Sanofi’s Zimulti Goes To Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic & Metabolic Drugs Advisory Committee will review the obesity agent, formerly known as Acomplia, June 13.